Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsConsultation-liaison psychiatry

Psych MEQs / SAQs · Consultation-liaison psychiatry

Stroke psychiatry — PSD, location myth, capacity (MEQ)

FRANZCP-style MEQ on post-stroke depression, Carson location myth, SSRI monitoring with dual antiplatelets, FLAME vs FOCUS/AFFINITY/EFFECTS, and decision-specific capacity.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 68-year-old woman is 6 weeks after left MCA ischaemic stroke with residual mild expressive aphasia and right hemiparesis. She is on aspirin and clopidogrel. Rehab staff report tearfulness, anhedonia, early waking, and passive suicidal ideation; she has stopped participating in physiotherapy. A junior doctor says depression is 'inevitable with a left frontal lesion' and asks for fluoxetine 'for the arm and the mood.' She wants to sign sale papers for her house this week so her son can 'take over.' (i) Formulate the psychiatric issues and correct the location claim. (ii) Outline assessment including aphasia and risk. (iii) Give an evidence-informed treatment plan with named agents/doses and trial literacy (prevention vs motor recovery). (iv) Address capacity for the house sale and disposition. (20 marks)

Model answer

Reveal model answer

(i) Formulation and location. Concurrent post-stroke depression (depressive disorder due to another medical condition): anhedonia, insomnia, passive SI, rehab withdrawal at 6 weeks — PSD affects roughly one-third of survivors at some point and worsens participation.[1][2] Correct the junior doctor: lesion location alone is not a reliable diagnostic determinant of PSD (Carson systematic review); left frontal history is teaching colour, not a rule that makes clinical assessment unnecessary.[3][7] Distinguish from pure apathy or emotionalism if features fit, but here depressive syndrome is primary.

(ii) Assessment. Stroke dossier (territory, disability, dual antiplatelets), collateral, aphasia-adapted MSE, suicide risk, medical drivers of non-engagement, cognitive screen. PHQ-type tools if language allows; otherwise observational/therapy metrics.[1][7]

(iii) Treatment. Multimodal AHA/ASA-aligned care: rehab psychology/behavioural activation adapted for aphasia; social support; treat pain/sleep.[1] Antidepressant example: sertraline 25–50 mg oral daily titrate, or escitalopram 5–10 mg oral daily (often 5 mg if older/frail), monitoring bleeding with dual antiplatelets, sodium, falls, QTc (especially escitalopram/citalopram), and early suicide risk; Cochrane supports pharmacological and psychological treatment options with evidence-quality caveats.[6][7] Trial literacy: Robinson JAMA 2008 showed prevention with escitalopram or problem-solving therapy in non-depressed patients — different question from treating established PSD.[4] Do not start fluoxetine solely for motor recovery; after FLAME enthusiasm, large pragmatic trials (FOCUS and related AFFINITY/EFFECTS programme) do not support routine fluoxetine for functional outcome — treat mood on psychiatric grounds.[5]

(iv) Capacity and disposition. House sale is a high-stakes, decision-specific capacity problem: test understanding, retention, weighing, communication with speech support. Nodding or mild aphasia does not prove valid weighing, especially with depression-related hopelessness. Pause major transactions; involve social work/legal substitute pathways under local law; reassess after mood treatment. Disposition: suicide safety plan, stepwise rehab, community CL/GP follow-up, secondary prevention adherence support.[1][7]

Common errors

Equating left frontal lesion with automatic PSD diagnosis; prescribing fluoxetine only for the hemiparetic arm; ignoring bleeding/hyponatraemia; equating aphasia with global incapacity; omitting suicide risk.[3][5][1]

Examiner notes

Reward myth correction (Carson), named prevention RCT (Robinson 2008), SSRI practical dosing with antithrombotic caution, FOCUS-level trial literacy, and sophisticated capacity reasoning.[3][4][5]

References

  1. [1]Towfighi A, Ovbiagele B, El Husseini N, Hackett ML, et al. Poststroke Depression: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Stroke, 2017.PMID 27932603
  2. [2]Hackett ML, Pickles K Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies Int J Stroke, 2014.PMID 25117911
  3. [3]Carson AJ, MacHale S, Allen K, Lawrie SM, et al. Depression after stroke and lesion location: a systematic review Lancet, 2000.PMID 10963248
  4. [4]Robinson RG, Jorge RE, Moser DJ, Acion L, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial JAMA, 2008.PMID 18505948
  5. [5]FOCUS Trial Collaboration Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial Lancet, 2019.PMID 30528472
  6. [6]Allida SM, Hsieh CF, Cox KL, Patel K, et al. Pharmacological, non-invasive brain stimulation and psychological interventions, and their combination, for treating depression after stroke Cochrane Database Syst Rev, 2023.PMID 37417452
  7. [7]Robinson RG, Jorge RE Post-Stroke Depression: A Review Am J Psychiatry, 2016.PMID 26684921